Last reviewed · How we verify
NCT04963868: TTSRNP
Timing of Transmural Stent Removal in Necrotizing Pancreatitis
NA trial testing Stent removed by the novel strategy in Acute Pancreatitis in 156 participants. Status unknown.
1 June 2024
Quick facts
| Lead sponsor | The First Affiliated Hospital of Nanchang University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 156 |
| Start date | 1 January 2022 |
| Primary completion | 1 June 2024 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Stent removed by the novel strategy
- Stent removed by the conventional strategy
Conditions studied
- Acute Pancreatitis — all drugs for Acute Pancreatitis →
- Necrotizing Pancreatitis — all drugs for Necrotizing Pancreatitis →
- Walled-Off Necrosis — all drugs for Walled-Off Necrosis →
Sponsor
The First Affiliated Hospital of Nanchang University
Who can join
18 and older, any sex, with Acute Pancreatitis or Necrotizing Pancreatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Although metal stents have been widely used in the endoscopic step-up approach for necrotizing pancreatitis, the exact timing of transmural stent removal has not been well studied. In this prospective, open-label, randomized controlled study, we recruited and enrolled consecutive patients with necrotizing pancreatitis undergoing endoscopic transmural necrosectomy. Eligible participants were randomly assigned to case group (a novel strategy in which the stents were removed during the last necrosectomy when the necrosectomy endpoint was achieved) and control group (the conventional strategy in which the stents were removed after the last necrosectomy when clinical symptoms were relieved and fluid was nearly completely resolved confirmed by imaging). The primary endpoint was the incidence of composite complications within three months of enrollment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04963868
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Pancreatitis
Currently open trials in the same condition.
- NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
- NCT06899087 — DEciphering CIrculating SIgnatures Of Infected Pancreatic Necrosis · recruiting
- NCT07322978 — Incidence of Splanchnic Venous Thrombosis in Acute Pancreatitis and it's Correlation With Severity of Pancreatitis · recruiting
- NCT03547232 — Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial) · Phase 4 · recruiting
- NCT06401577 — Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics · recruiting
Other The First Affiliated Hospital of Nanchang University trials
Trials by the same sponsor.
- NCT06639516 — Therapeutic Effect of Bifidobacterium Longum in Patients with Acute Pancreatitis: a Randomized, Double-Blind, Placebo-Co · NA · not yet recruiting
- NCT07136961 — Efficacy and Safety of Robotic-assisted Bronchoscopy Combined With the ICNVA Strategy in Biopsy of Peripheral Pulmonary · NA · active not recruiting
- NCT06999031 — A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma · EARLY_PHASE1 · recruiting
- NCT06751966 — Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment · NA · recruiting
- NCT06752057 — Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04963868 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Nanchang University
- Last refreshed: 15 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04963868.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing